5-Fluorouracil: mechanisms of resistance and reversal strategies.

Zhang N, Yin Y, Xu SJ, Chen WS. · 2008

Read 5-Fluorouracil: mechanisms of resistance and reversal strategies. by Zhang N, Yin Y, Xu SJ, Chen WS. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6244944.txt.

Introduction

Zhang and co-authors review resistance to a cancer drug called 5-fluorouracil. The drug has treated colon cancer since 1957. It is also used for breast and head and neck cancers. It mimics a building block of DNA and RNA. The review appeared in Molecules.

Inserted into DNA and RNA, the drug kills cancer cells. Yet resistance limits its use in the clinic. Response rates for advanced colon cancer stay low with the drug alone. The review first explains how the drug acts. It then covers studies of resistance mechanisms. A third part covers gene-finding with microarray tools. The authors detail how resistance starts and how it might be reversed. That knowledge could restore the drug's value.

Catalog record

CREATORZhang N, Yin Y, Xu SJ, Chen WS.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE53 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6244944

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies By Ning Zhang, Ying Yin, Sheng-Jie Xu, Wei-Shan Chen Published in: Molecules DOI: 10.3390/molecules13081551 ABSTRACT The purpose of this work is to review the published studies on the mechanisms of action and resistance of 5-fluorouracil. The review is divided into three main sections: mechanisms of anti-tumor action, studies of the resistance to the drug, and procedures for the identification of new genes involved in resistance with microarray techniques. The details of the induction and reversal of the drug resistance are also described. INTRODUCTION 5-Fluorouracil (5-FU) is still a widely used anticancer drug. Since 1957, it has played an important role in the treatment of colon cancer and is used for patients with breast and other cancers, like those of the head and neck [1]. 5-FU is a heterocyclic aromatic organic compound with a structure similar to that of the pyrimidine molecules of DNA and RNA; it is an analogue of uracil with a fluorine atom at the C-5 position in place of hydrogen [2]. Only one crystal structure is reported in the literature for pure 5-FU, in which the compound crystallizes with four molecules in the asymmetric unit and the molecule adopts a hydrogen-bonded sheet structure [3,4]. Due to its structure, 5-FU interferes with nucleoside metabolism and can be incorporated into RNA and DNA, leading to cytotoxicity and cell death [5,6]. Over the past 50 years, despite its many advantages, clinical applications have been greatly limited due to drug resistance. The overall response rate for advanced colorectal cancer of 5-FU alone is still only 10–15% [7], and the combination of 5-FU with other anti-tumor drugs has merely improved the response rates to 40–50% [8]. Therefore, new strategies for therapy and resistance reversal are urgently needed. Meanwhile, understanding the mechanisms by which tumors become resistant to 5-FU is an essential step towards predicting or overcoming that resistance. Fortunately, the development of microarray techniques offers us a chance to identify new genes which have key roles in drug resistance. Now, we can move forward to investigate the mechanism of these molecules, which might contribute to clinical chemotherapy in the future. MECHANISM OF ACTION In mammalian cells, 5-FU is converted to fluorodeoxyuridine monophosphate (FdUMP), which forms a stable complex with thymidylate synthase (TS), and thus inhibits deoxythymidine mono-phosphate (dTMP) production. dTMP is essential for DNA replication and repair and its depletion therefore causes cytotoxicity [9,10]. Dihydropyrimidine dehydrogenase (DPD)-mediated conversion of 5-FU to dihydrofluorouracil (DHFU) is the rate-limiting step of 5-FU catabolism in normal and tumor cells. Up to 80% of administered 5-FU is broken down by DPD in the liver [11]. TS inhibition TS, an essential enzyme for catalyzing the biosynthesis of thymidylate, is implicated in the regulation of protein synthesis and apoptotic processes [12,13]. TS catalyzes the methylation of deoxyuridine monophosphate (dUMP) to dTMP, for which 5,10-methylenetetrahydrofolate (CH2THF) is the methyl donor, and finally provides with the reaction thymidylate to maintain DNA replication and repair [14]. The reaction has a seriatim binding sequence, and dUMP binds at the active site before CH2THF does. Then the reaction is initiated by the nucleophilic addition of the active site Cys 146 (numbering of amino acid residues used is according to the sequence of EcTS) to the pyrimidine C (6)atom of dUMP. Specifically, at the onset of catalysis, the binding position and orientation of the substrate, if correctly adopted, support an efficient binding of the cofactor, and then allow the formation of the ternary TS–dUMP–CH2THF complex, and the subsequent reaction [15]. Research has indicated that 5-FU exerts its anticancer effects mainly through inhibition of TS, for which the pathways have not been fully interpreted. Santi has pointed out that the formation of the ternary TS–FdUMP–CH2THF complex is time-dependent, and the reaction stops as the fluorine substituent fails to dissociate from the pyrimidine ring, resulting in a slowly reversible inactivation of the enzyme [16]. Reduction of dTMP leads to downstream depletion of deoxythymidine triphosphate (dTTP), which induces perturbations in the levels of the other deoxynucleotides (dATP, dGTP and dCTP). Finally the imbalances (the ATP/dTTP ratio specifically) are thought to severely disrupt DNA synthesis and repair, resulting in lethal DNA damage [17,18]. Accumulation of dUMP, which might subsequently lead to increased levels of deoxyuri-dine triphosphate (dUTP), can be misincorporated into DNA, and FdUTP, the metabolic product of 5-FU has the same action [19]. Furthermore, repairing enzyme uracil-DNA-glycosy-lase (UDG) is suggested to be useless in the presence of high (F) dUTP/dTTP ratios and only results in further false DNA repair [20]. DNA and RNA misincorporation 5-FU is a pyrimidine analogue that can be misincorporated into RNA and DNA in place of uracil or thymine. The interference with the normal biosynthesis or function of nucleic acids is therefore another possible mechanism of action for 5-FU. 5-FU can be misincorporated into DNA of drug-treated cells, and accumulation of 5-FU in the genome, rather than uracil excision, is correlated with 5-FU cytotoxicity in mammalian cells [21]. It can also be misincorporated into RNA, and evidence suggests that RNA-based effects play a significant role in its cytotoxicity. Experiments in yeast show that defects in the nuclear RNA exosome subunit Rrp6p could cause hypersensitivity to 5-FU. Genetic analyses suggest that while a DNA repair mutation, apn1-Δ causes sensitivity to 5-FU-induced DNA damage, and an rrp6-Δ mutation causes hypersensitivity, due to the RNA-based effects of 5-FU [22]. The results suggest that rRNA maturation is an important target for 5-FU [23,24,25]. 5-FU has also been shown to enhance exosome-dependent accumulation of polyadenylated rRNAs [26]. And there is evidence that 5-FU inhibits premRNA splicing, through its effect on pseudouridylation of U2 snRNA [27]. The action of 5-FU is not only inhibiting the processing of pre-rRNA into mature rRNA, but also disrupting post-transcriptional modification of tRNAs and the assembly activity of snRNA/protein complexes, thereby inhibiting splicing of pre-mRNA [28]. 5-FU-containing RNA can also inhibit pseudouridylation, the most abundant post-transcriptional modification of noncoding RNA. Results suggest that Cbf5p binds tightly to substrates containing 5-FU, causing their degradation by the TRAMP/exosome-mediated RNA surveillance pathway. And the RNA-based 5-FU toxicity requires the pseudouridylation activity of Cbf5p, and sequestration of Cbf5p to a particular guide RNA reduced Cbf5p-dependent 5-FU toxicity [29]. [Figure: a) 5-FU, b) uracil.] Assisted modulation Leucovorin Leucovorin (LV), which enters the cell via the reduced folate carriers and is anabolized to CH2THF, increases the intracellular CH2THF pool, thereby enhancing TS inhibition by FdUMP [30]. During the procedure, CH2THF is polyglutamated by folylpolyglutamate synthetase. Polyglutamation not only increases the cellular retention of CH2THF, but also enhances the stabilization of its ternary complex with TS and FdUMP [31,32]. However, resistance to modulation of 5-FU by LV exists and decreased stability of ternary complexes appears to be the mechanism of acquired resistance to the LV modulation of fluoropyrimidine cytotoxicity, possibly due to mutation(s) of TS [33,34,35]. Interferons Interferons (IFNs) are pleiotropic cytokines that exert negative regulatory effects on the growth of normal and malignant cells in vitro and in vivo. Studies have reported that IFNs might enhance the cytotoxicity of 5-FU in various cancer cell lines. 5-FU might induce secretion of proteolytically processed mature and degraded IL-18 species, by inducing Caspase-1 and Caspase-3 activation. Conditioned medium from 5-FU-treated induces IFN-g production by activated T cells

Read the complete text